1. Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G. Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach. Int Immunopharmacol. 2017;52:136-42.

2. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011,19;475(7354):110-3.

3. Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol. 2014;14(6):509-15.

4. Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017,17;2(16).

5. Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol. 2016,2;7:21.

6. Castells MC. A New Era for Drug Desensitizations. J Allergy Clin Immunol Pract. 2015;3(4):639-40.